Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway

INTRODUCTION: Immunocompromised patients with B-cell depletion agents are at risk for persistence and/or severe SARS-COV-2 infection. We describe a case series of 21 COVID-19 patients under B cell depletion therapy, mostly treated with a combined therapy based on intravenous remdesevir (RDV) and ste...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Abramo, Alessandra, Vita, Serena, Maffongelli, Gaetano, Beccacece, Alessia, Agrati, Chiara, Cimini, Eleonora, Colavita, Francesca, Giancola, Maria Letizia, Cavasio, Alessandro, Nicastri, Emanuele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196078/
https://www.ncbi.nlm.nih.gov/pubmed/35711444
http://dx.doi.org/10.3389/fimmu.2022.911339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196078/
https://www.ncbi.nlm.nih.gov/pubmed/35711444
http://dx.doi.org/10.3389/fimmu.2022.911339

Ejemplares similares